Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KALVNASDAQ:ORICNASDAQ:SELBNASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALVKalVista Pharmaceuticals$12.18+2.4%$12.05$7.30▼$15.50$605.54M0.05416,378 shs542,938 shsORICORIC Pharmaceuticals$5.41+6.5%$5.84$3.90▼$14.67$384.59M1.37641,723 shs385,131 shsSELBSelecta Biosciences$1.06$0.81▼$1.99$136.76M0.84979,585 shs2.77 million shsSVRASavara$3.02+5.6%$2.91$2.26▼$5.11$521.70M0.441.30 million shs1.42 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALVKalVista Pharmaceuticals+2.35%-7.02%+6.01%+31.39%+0.83%ORICORIC Pharmaceuticals+6.50%-5.09%+9.96%-45.08%-39.82%SELBSelecta Biosciences0.00%0.00%0.00%0.00%0.00%SVRASavara+5.59%-7.93%+3.42%+9.82%-35.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKALVKalVista Pharmaceuticals3.9972 of 5 stars3.60.00.04.43.52.50.6ORICORIC Pharmaceuticals4.4746 of 5 stars4.52.00.04.32.71.70.6SELBSelecta BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara1.9232 of 5 stars3.40.00.00.03.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALVKalVista Pharmaceuticals 3.13Buy$24.83103.89% UpsideORICORIC Pharmaceuticals 3.00Buy$19.17254.28% UpsideSELBSelecta Biosciences 0.00N/AN/AN/ASVRASavara 2.83Moderate Buy$8.83192.49% UpsideCurrent Analyst Ratings BreakdownLatest KALV, SELB, SVRA, and ORIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025ORICORIC PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $12.005/6/2025ORICORIC PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/5/2025ORICORIC PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.004/8/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/28/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/26/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/26/2025KALVKalVista PharmaceuticalsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/20/2025ORICORIC PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.003/14/2025KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/13/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.002/26/2025ORICORIC PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $22.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.86 per shareN/AORICORIC PharmaceuticalsN/AN/AN/AN/A$3.42 per shareN/ASELBSelecta Biosciences$110.78M0.00N/A9.91$0.61 per share0.00SVRASavaraN/AN/AN/AN/A$1.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALVKalVista Pharmaceuticals-$126.64M-$3.72N/AN/AN/AN/A-103.92%-88.06%7/10/2025 (Estimated)ORICORIC Pharmaceuticals-$100.70M-$1.87N/AN/AN/AN/A-44.54%-40.72%N/ASELBSelecta Biosciences$35.38M-$0.22N/AN/AN/A-72.04%-44.13%-22.00%N/ASVRASavara-$54.70M-$0.47N/AN/AN/AN/A-58.89%-46.44%N/ALatest KALV, SELB, SVRA, and ORIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025ORICORIC Pharmaceuticals-$0.51-$0.42+$0.09-$0.42N/AN/A3/27/2025Q4 2024SVRASavara-$0.11-$0.13-$0.02-$0.13N/A$0.27 million2/18/2025Q4 2024ORICORIC Pharmaceuticals-$0.52-$0.51+$0.01-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AORICORIC PharmaceuticalsN/AN/AN/AN/AN/ASELBSelecta BiosciencesN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALVKalVista PharmaceuticalsN/A6.876.87ORICORIC PharmaceuticalsN/A10.5613.15SELBSelecta Biosciences0.214.184.18SVRASavara0.1317.7017.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALVKalVista PharmaceuticalsN/AORICORIC Pharmaceuticals95.05%SELBSelecta Biosciences41.95%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipKALVKalVista Pharmaceuticals10.50%ORICORIC Pharmaceuticals6.82%SELBSelecta Biosciences31.20%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKALVKalVista Pharmaceuticals10049.72 million44.23 millionOptionableORICORIC Pharmaceuticals8071.09 million67.09 millionOptionableSELBSelecta Biosciences64155.20 million106.78 millionOptionableSVRASavaraN/A172.75 million162.82 millionOptionableKALV, SELB, SVRA, and ORIC HeadlinesRecent News About These CompaniesSavara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor ConferenceMay 12 at 4:05 PM | businesswire.comFarallon Capital Management LLC Increases Stake in Savara Inc (NASDAQ:SVRA)May 11 at 7:40 AM | marketbeat.comBrokerages Set Savara Inc (NASDAQ:SVRA) Target Price at $8.83May 11 at 3:09 AM | americanbankingnews.comDeerfield Management Company L.P. Series C Increases Position in Savara Inc (NASDAQ:SVRA)May 10 at 7:28 AM | marketbeat.comMaharashtra News: Palghar MP Hemant Savara Urges Special Relief Package For Fisherfolk After Storm DamageMay 9, 2025 | freepressjournal.inRaymond James Financial Inc. Buys Shares of 259,798 Savara Inc (NASDAQ:SVRA)May 9, 2025 | marketbeat.comSavara Inc (NASDAQ:SVRA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 8, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Makes New Investment in Savara Inc (NASDAQ:SVRA)May 5, 2025 | marketbeat.comSavara (SVRA) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comMarshall Wace LLP Invests $1.11 Million in Savara Inc (NASDAQ:SVRA)May 2, 2025 | marketbeat.comSavara Announces Participation in the Upcoming Citizens Life Sciences ConferenceMay 1, 2025 | businesswire.comEmerald Mutual Fund Advisers Trust Makes New Investment in Savara Inc (NASDAQ:SVRA)May 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 4,637,930 Shares of Savara Inc (NASDAQ:SVRA)May 1, 2025 | marketbeat.comNantahala Capital Management LLC Has $23.10 Million Stock Holdings in Savara Inc (NASDAQ:SVRA)April 30, 2025 | marketbeat.comMaharashtra News: Palghar MP Hemant Savara Stops To Help Injured Woman On Mumbai-Ahmedabad Highway (VIDEO)April 28, 2025 | freepressjournal.inSwift Action by MP Dr Hemant Savara Saves Road Accident VictimApril 28, 2025 | devdiscourse.comSavara: Make-It-Or-Break-It Molbreevi BLA FilingApril 21, 2025 | seekingalpha.comJPMorgan Chase & Co. Grows Stock Position in Savara Inc (NASDAQ:SVRA)April 21, 2025 | marketbeat.comSavara (NASDAQ:SVRA) Shares Up 4.1% - Here's What HappenedApril 17, 2025 | marketbeat.comAffinity Asset Advisors LLC Lowers Stock Position in Savara Inc (NASDAQ:SVRA)April 17, 2025 | marketbeat.comSavara Inc. Announces Equity Awards for New EmployeesApril 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKALV, SELB, SVRA, and ORIC Company DescriptionsKalVista Pharmaceuticals NASDAQ:KALV$12.18 +0.28 (+2.35%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$12.20 +0.02 (+0.20%) As of 07:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.ORIC Pharmaceuticals NASDAQ:ORIC$5.41 +0.33 (+6.50%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$5.48 +0.07 (+1.29%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Selecta Biosciences NASDAQ:SELBSelecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.Savara NASDAQ:SVRA$3.02 +0.16 (+5.59%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$3.03 +0.01 (+0.46%) As of 07:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
